Nom du produit:4-(4-Methylpiperazin-1-ylmethyl)benzoic acid
IUPAC Name:4-[(4-methylpiperazin-1-yl)methyl]benzoic acid
- CAS：106261-48-7
- Formule moléculaire：C13H18N2O2
- Pureté：95%+
- Numéro de catalogue：CM162131
- Poids moléculaire：234.3
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:106261-48-7
- Formule moléculaire:C13H18N2O2
- Point de fusion:-
- Code SMILES:CN1CCN(CC1)CC2=CC=C(C(=O)O)C=C2
- Densité:
- Numéro de catalogue:CM162131
- Poids moléculaire:234.3
- Point d'ébullition:
- N° Mdl:MFCD01632530
- Stockage:Store at room temperature.
Category Infos
- Piperazines
- Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- Risvodetinib
- Inhibikase Therapeutics’s Risvodetinib (IkT-148009) has been granted Orphan Drug Designation by the U.S. FDA for the treatment of Multiple System Atrophy (MSA). MSA is a rapidly progressive rare condition of the nervous system that causes gradual damage to nerve cells in the brain, and shares many symptoms with Parkinson's disease. This neurological disorder has an estimate an average of 0.6 to 0.7 new cases per 100,000 people yearly.
The non-receptor tyrosine kinase Abelson, c-Abl is shown to be implicated in the initiation and progression of α-synuclein (α-syn) pathogenesis and neurodegeneration. Risvodetinib is a brain-penetrant selective inhibitor of c-Abl1 and Abl2 undergoing Phase 2 clinical studies.
Recherche 
+86 21 5895 0110 
